Editas Medicine’s new leadership team on Wednesday reiterated a promise to deliver clinical updates on two CRISPR-based treatments before the end of the year — data the troubled biotech hopes will ease investor doubts about its gene-editing technology.
Other CRISPR companies command multibillion-dollar valuations, but Editas, one of the originals, trades below its IPO price after years of management upheaval and clinical delay.
“I’m pleased with the progress we’ve made this quarter,” said Editas CEO Gilmore O’Neill on the company’s quarterly conference call. “Operationally, with our focus on clinical advancement, execution is our top priority.”
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect